CHICAGO—Two potassium-competitive acid blockers were associated with a potential healing advantage for erosive esophagitis over a standard dose of a proton pump inhibitor in separate randomized, double-blind trials.
In both studies, the rate of EE healing was higher with the P-CABs than a 30-mg once-daily dosage of the PPI lansoprazole, and in one study, the healing was faster. But the trials tested noninferiority, and experts say larger trials are needed to confirm the role of these